|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 59.5 EUR | +0.37% |
|
+3.05% | +1.40% |
| May. 02 | DANONE : UBS keeps its Buy rating | ZD |
| May. 02 | Danone: acquisition of Functional Formularies | CF |
| Entry price | Target | Stop-loss | Potential |
|---|---|---|---|
| €51.74 | €54.2 | €50.7 | +4.75% |
● The company has a good ESG score relative to its sector, according to Refinitiv.
● The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
● As estimated by analysts, this group is among those businesses with the lowest growth prospects.
● For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
| 1st Jan change | Capi. | |
|---|---|---|
| +1.40% | 41.13B | |
| -2.39% | 275B | |
| -1.70% | 95.5B | |
| -2.00% | 44.01B | |
| +9.84% | 41.41B | |
| +8.54% | 39.91B | |
| -12.79% | 31.14B | |
| -4.77% | 29.23B | |
| +14.15% | 25.26B | |
| -4.34% | 23.96B |
DANONE 
